Table 1. Baseline Characteristics of Study Participants.
| Controls | HCV+ individuals evaluated in functional experiments | HCV+ individuals included in whole blood phenotype study | |
|---|---|---|---|
| n | 51 | 29 | 50 |
| Sex (male, female)a | M26, F25 | M21, F8 | M39, F11 |
| Mean age | 35.0 ± 10.8 | 48.9 ± 12.5 | 49.4 ± 9.9 |
| Ethnicity (%White) | 88% | 86% | 92% |
| HCV Genotype | |||
| 1 | 22/29 | 33*/49 | |
| 2 | 1/29 | 6/49 | |
| 3 | 6/29 | 8/49 | |
| 4 | 0/29 | 3*/49 | |
| Fibrosis Stageb | |||
| 0–2 | 20/28 | 35/44 | |
| 2–4 | 8/28 | 9/44 | |
| Mean HCV RNA (IU/ml) | 7.58x106 ± 1.1x107 | ||
| Mean ALTb | 90 ± 58 |
a M (male), F (female)
b measured by liver biopsy (Metavir system) or by fibroscan
*One participant with genotype 1 and 4 co-infection
Note: There is no fibrosis or genotype data for some HCV+ individuals.